Vitura Health Limited (ASX: VIT) - Share Price
Current share price for VIT : $0.027 0.002 (8%)+
Vitura Health Limited (VIT), an ASX-listed company, is involved in the operation of its digital health platform, Canview, the sale and distribution of medicinal cannabis and other products and the operation of its growing number of telehealth-based clinic businesses.
VIT General Information +
| ASX Code | VIT |
| Website | http://www.vitura.com.au |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 17 |
| VIT Share Price | $0.027 |
| Day High | $0.027 |
| Day Low | $0.025 |
| Last Close | $0.025 |
| VIT Share Price Movement | $0.00 ( 8% ) |
Prices as at 13:50, 2 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Vitura Health Limited (VIT) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| HFResult | 0.2¢ | 100% | 5 Sep 2025 | 30 Sep 2025 | - | - | - |
| HFResult | 1¢ | 100% | 4 Sep 2023 | 28 Sep 2023 | - | - | - |
| HFResult | 1¢ | 100% | 16 Sep 2022 | 11 Oct 2022 | - | - | - |
See all dividends from Vitura Health Limited (VIT) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Vitura Health Limited (VIT) price-sensitive announcements
VIT - Former CEO Legal Action Initiated
Vitura Health Limited, a diversified digital health business listed on the ASX, announced
Vitura Health Limited (VIT)
20 May 2026 | 9:37 AM
20 May 2026 | 9:37 AM
VIT - Business Transformation Update
Vitura Health Limited has announced a business transformation update which results in appr
Vitura Health Limited (VIT)
28 Apr 2026 | 8:21 AM
28 Apr 2026 | 8:21 AM
VIT - Doctors on Demand Performance Update
Vitura Health Limited's Doctors on Demand telehealth service has reached significant miles
Vitura Health Limited (VIT)
21 Apr 2026 | 8:14 AM
21 Apr 2026 | 8:14 AM
VIT - Appointment of Chief Executive Officer
Vitura Health Limited, a leading digital health platform in Australia, announced the appoi
Vitura Health Limited (VIT)
2 Apr 2026 | 9:55 AM
2 Apr 2026 | 9:55 AM
Vitura Health Limited (VIT) Recent ASX Announcements
VIT Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | $2.88 | $0.50 | -89.40% | 15.80 | 0.20 | 2.40% | 100.0% |
| 2024A | $27.76 | $4.90 | 103.30% | 5.50 | 0.00 | 0.00% | 0.0% |
| 2023A | $13.74 | $2.40 | 103.40% | 20.40 | 1.00 | 2.00% | 100.0% |
VIT Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Clarity Pharmaceuticals Ltd (CU6) | $798M | 0.3002 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $2,250M | -0.7857 | 0.0743 | 1.2000 | 76.2785 | 71.0000 | 32.2727 | 0.00% | 0.00% | 0.00% |
| Vitura Health Limited (VIT) | $17M | -0.8943 | 0.0000 | 0.0000 | 4.8077 | 0.0000 | 0.0000 | 8.00% | 0.00% | 0.00% |
VIT Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.20 | 4.81 | 0.34 | 0.00 |
| Market | 0.29 | 13.20 | 1.14 | 0.67 |
| Sector | 0.44 | 26.00 | 2.46 | 1.91 |
VIT Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Robert Iervasi | Non-Executive Chairman, Non-Executive Director | 12 Feb 2024 |
| Mr Shane Francis Tanner | Non-Executive Director | 27 Nov 2024 |
| Ms Rebecca Jayne Wilson | Non-Executive Director | 27 Nov 2024 |
| Mr Daniel Francis Birch | Non-Executive Director | 27 Nov 2024 |
Vitura Health Limited (VIT) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 30 Sep 2025 | FOGARTY, Gerard | Buy | Indirect Shares | 10,428 | $0.064 | $663.951 |
| 4 Mar 2025 | FOGARTY, Gerard | Buy | Indirect Shares | 332,000 | $0.075 | $24,900.000 |
| 27 Feb 2025 | WILSON, Rebecca | Buy | Indirect Shares | 228,000 | $0.087 | $19,835.912 |
See all changes in directors' interest & trades for Vitura Health Limited (VIT) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
VIT Management
| Name | Position |
|---|---|
| Ryan J. Tattle | Chief Revenue Officer |
| Geoff Cockerill | Chief Executive Officer |
| Michael Sapountzis | Company Secretary |
VIT Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Vitura Health Limited (VIT). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 114,464,236 (17.28%) | AFO Investments Pty Ltd |
| 85,621,544 (12.92%) | Benjamin David Ngahuia Jansen |
| 55,176,065 (8.33%) | Cronos Global Holdings Inc |
| 50,101,072 (7.56%) | Jessimine Charles Kiritea Jansen |
| 50,101,079 (7.56%) | Guy Rothwell Headley |
| 36,079,345 (5.44%) | Matua Hasyo Charlie Jansen |
VIT Calendar of Events
| Date | Event |
|---|---|
| 24 February 2027 | Report (Interim) |
| 21 October 2026 | Report (Annual) |
| 26 August 2026 | Report (Prelim) |
| 24 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
